O
Olga Shvetz
Researcher at Kaplan Medical Center
Publications - 6
Citations - 110
Olga Shvetz is an academic researcher from Kaplan Medical Center. The author has contributed to research in topics: Clinical endpoint & Lenalidomide. The author has an hindex of 3, co-authored 6 publications receiving 34 citations.
Papers
More filters
Journal ArticleDOI
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Yael C Cohen,Yael C Cohen,Mor Zada,Mor Zada,Shuang-Yin Wang,Chamutal Bornstein,Eyal David,Adi Moshe,Baoguo Li,Shir Shlomi-Loubaton,Moshe E. Gatt,Chamutal Gur,Chamutal Gur,Noa Lavi,Chezi Ganzel,Efrat Luttwak,Efrat Luttwak,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Oren Pasvolsky,Oren Pasvolsky,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky-Dolberg,Olga Shvetz,Meirav Laiba,Ofer Shpilberg,Najib Dally,Irit Avivi,Irit Avivi,Assaf Weiner,Ido Amit +34 more
TL;DR: In this article, a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) was conducted to study the molecular dynamics of MM resistance mechanisms.
Journal ArticleDOI
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Yael C Cohen,Hila Magen,Hila Magen,Noa Lavi,Moshe E. Gatt,Evgeni Chubar,Nethanel Horowitz,Natalia Kreiniz,Tamar Tadmor,Svetlana Trestman,Roy Vitkon,Ory Rouvio,Olga Shvetz,Adir Shaulov,Tomer Ziv-Baran,Irit Avivi,Irit Avivi +16 more
TL;DR: Ixazomib-based combinations are efficacious and safe regimens in RRMM patients in the real-world setting, regardless to cytogenetic risk, with a PFS of 24 months comparable with clinical trial data.
Journal ArticleDOI
Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints
Yael C Cohen,Mor Zada,Moshe E. Gatt,Noa Lavi,Chezi Ganzel,Shuang-Yin Wang,Assaf Weiner,Guy Ledergor,Evgeni Chubar,Ory Rouvio,Iuliana Vaxman,Iuliana Vaxman,Mouna Ballan,Tamar Tadmor,Anatoly Nemets,Osnat Jarchowcky Dolberg,Olga Shvetz,Ofer Shpilberg,Nagib Deli,Irit Avivi,Irit Avivi,Ido Amit +21 more
TL;DR: A high resolution molecular tool of massively-parallel single-cell RNA-sequencing (MARS-seq) calibrated for this trial aimed to identify gene expression signatures associated with clinical response and resistance, and compared them to NDMM and to healthy age and sex matched controls.
Journal ArticleDOI
Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma
Ohad Benjamini,David Lavie,Eldad J. Dann,Chava Perry,Ory Rouvio,Olga Shvetz,Anatoly Nemets,Ruth Perets,Revital Saban,Avichai Shimoni,Dina Ben-Yehuda,Arnon Nagler,Abraham Avigdor +12 more
TL;DR: The real life experience confirms the efficacy and safety of nivolumab in very heavily pretreated young and elderly patients with cHL eligible as well as ineligible for autologous HSCT and brentuximab vedotin.
Journal ArticleDOI
Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience
Noam Benyamini,Adir S,Moshe E. Gatt,Yael C Cohen,Irit Avivi,Irit Avivi,Svetlana Trestman,Olga Shvetz,Tamar Tadmor,Najib Dally,Yevgeny Chober,Hila Magen,Chezi Ganzel,Osnat Jarchowcky Dolberg,Celia Suriu,Noa Lavi +15 more
TL;DR: Daratumumab has been recently introduced to the early relapsed multiple myeloma setting, providing significant improvement in progression-free survival when administered in combination with IMIDs or PIs.